Volume 92 Issue 33 | p. 5 | News of The Week
Issue Date: August 18, 2014

Mannkind Gets A Deal With Sanofi

Pharmaceuticals: Struggling firm finds a marketing partner for its inhaled-insulin product
Department: Business
Keywords: diabetes, biopharmaceuticals, insulin, drug delivery

The drug company MannKind has signed up Sanofi as a partner to sell Afrezza, the inhaled insulin it has long labored to get to market. FDA okayed the product in late June, fully five years after California-based MannKind applied for approval. The firms intend to launch Afrezza in the U.S. in early 2015.

Sanofi will pay MannKind $150 million up front, and loan it up to $175 million, to . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society